Logo image of LXEO

LEXEO THERAPEUTICS INC (LXEO) Stock Fundamental Analysis

NASDAQ:LXEO - Nasdaq - US52886X1072 - Common Stock - Currency: USD

4.09  -0.42 (-9.31%)

Premarket: 4 -0.09 (-2.2%)

Fundamental Rating

1

Taking everything into account, LXEO scores 1 out of 10 in our fundamental rating. LXEO was compared to 559 industry peers in the Biotechnology industry. LXEO may be in some trouble as it scores bad on both profitability and health. LXEO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

LXEO had negative earnings in the past year.
In the past year LXEO has reported a negative cash flow from operations.
LXEO had negative earnings in each of the past 5 years.
LXEO had a negative operating cash flow in each of the past 5 years.
LXEO Yearly Net Income VS EBIT VS OCF VS FCFLXEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -86.78%, LXEO is not doing good in the industry: 72.81% of the companies in the same industry are doing better.
LXEO's Return On Equity of -123.78% is in line compared to the rest of the industry. LXEO outperforms 41.32% of its industry peers.
Industry RankSector Rank
ROA -86.78%
ROE -123.78%
ROIC N/A
ROA(3y)-58.41%
ROA(5y)-45.95%
ROE(3y)-74.86%
ROE(5y)-56.75%
ROIC(3y)N/A
ROIC(5y)N/A
LXEO Yearly ROA, ROE, ROICLXEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LXEO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LXEO Yearly Profit, Operating, Gross MarginsLXEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for LXEO has been increased compared to 1 year ago.
The debt/assets ratio for LXEO has been reduced compared to a year ago.
LXEO Yearly Shares OutstandingLXEO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
LXEO Yearly Total Debt VS Total AssetsLXEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

Based on the Altman-Z score of -3.67, we must say that LXEO is in the distress zone and has some risk of bankruptcy.
LXEO's Altman-Z score of -3.67 is in line compared to the rest of the industry. LXEO outperforms 46.87% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that LXEO is not too dependend on debt financing.
LXEO has a Debt to Equity ratio (0.01) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -3.67
ROIC/WACCN/A
WACCN/A
LXEO Yearly LT Debt VS Equity VS FCFLXEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

LXEO has a Current Ratio of 3.42. This indicates that LXEO is financially healthy and has no problem in meeting its short term obligations.
LXEO's Current ratio of 3.42 is on the low side compared to the rest of the industry. LXEO is outperformed by 60.47% of its industry peers.
LXEO has a Quick Ratio of 3.42. This indicates that LXEO is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.42, LXEO perfoms like the industry average, outperforming 41.14% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.42
Quick Ratio 3.42
LXEO Yearly Current Assets VS Current LiabilitesLXEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for LXEO have decreased strongly by -22.28% in the last year.
EPS 1Y (TTM)-22.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -1.48% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-1.45%
EPS Next 2Y9.33%
EPS Next 3Y4.61%
EPS Next 5Y-1.48%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LXEO Yearly Revenue VS EstimatesLXEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
LXEO Yearly EPS VS EstimatesLXEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LXEO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LXEO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LXEO Price Earnings VS Forward Price EarningsLXEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LXEO Per share dataLXEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.33%
EPS Next 3Y4.61%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LXEO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEXEO THERAPEUTICS INC

NASDAQ:LXEO (6/12/2025, 8:06:57 PM)

Premarket: 4 -0.09 (-2.2%)

4.09

-0.42 (-9.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/bmo
Earnings (Next)N/A N/A
Inst Owners103.17%
Inst Owner Change-4.93%
Ins Owners1.35%
Ins Owner Change6.07%
Market Cap135.79M
Analysts86.15
Price Target19.38 (373.84%)
Short Float %9.8%
Short Ratio2.8
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-9.32%
Min EPS beat(2)-23.91%
Max EPS beat(2)5.26%
EPS beat(4)2
Avg EPS beat(4)-9.5%
Min EPS beat(4)-28.59%
Max EPS beat(4)9.25%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10.14%
PT rev (3m)-14.74%
EPS NQ rev (1m)12.86%
EPS NQ rev (3m)13.58%
EPS NY rev (1m)0.27%
EPS NY rev (3m)-1.82%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.54
P/tB 1.54
EV/EBITDA N/A
EPS(TTM)-3.3
EYN/A
EPS(NY)-2.48
Fwd EYN/A
FCF(TTM)-2.66
FCFYN/A
OCF(TTM)-2.65
OCFYN/A
SpS0
BVpS2.65
TBVpS2.65
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -86.78%
ROE -123.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.41%
ROA(5y)-45.95%
ROE(3y)-74.86%
ROE(5y)-56.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.42
Quick Ratio 3.42
Altman-Z -3.67
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)122.1%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-22.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.57%
EPS Next Y-1.45%
EPS Next 2Y9.33%
EPS Next 3Y4.61%
EPS Next 5Y-1.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-61.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year26.27%
EBIT Next 3Y10.69%
EBIT Next 5YN/A
FCF growth 1Y-50.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.89%
OCF growth 3YN/A
OCF growth 5YN/A